The live measles vaccine (Vaccinum morbillorum culturarum vivum siccum)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceVaccine for measles preventionVaccine for measles prevention
Dosage form: & nbsplyophilizate for the preparation of a solution for subcutaneous administration
Composition:

One inoculation dose (0.5 ml) contains:

- not less than 1000 tissue cytopathogenic doses (TCD50) measles virus;

- stabilizer - a mixture of 0.04-0.08 ml of LS-18 and 0.001-0.002 g of gelatin

- or a mixture of 0.005-0.01 g of sorbitol and gelatin;

- gentamycin sulfate - no more than 10 mcg.

Description:The preparation is a homogeneous porous mass of yellow-pink or pink.
Pharmacotherapeutic group:MIBP vaccine
ATX: & nbsp

J.07.B.D.01   Measles virus - live attenuated

J.07.B.D   Vaccine for measles prevention

Pharmacodynamics:

The live measles live vaccine, lyophilizate for the preparation of a solution for subcutaneous administration, is prepared by culturing the vaccine strain of measles virus Leningrad-16 (L-16) on the primary culture of quail cells.

The vaccine stimulates the production of antibodies to measles virus in at least 95% of seronegative children on days 21-28 after vaccination. The drug meets WHO requirements.

Indications:

The vaccine is intended for routine and emergency measles prevention.Routine vaccinations are carried out twice at the age of 12-15 months and 6 years for children who do not have measles.

Children born from seronegative measles virus to the virus are vaccinated at the age of 8 months and further - in accordance with the vaccination schedule at 14-15 months and 6 years. The interval between vaccination and re-vaccination should be at least 6 months.

Emergency prophylaxis is administered to children from 12 months of age, adolescents and adults who have contact with a patient who has not had measles, and who has not previously been vaccinated against the infection. In the absence of contraindications, the vaccine is administered no later than 72 hours after contact with the patient.

Contraindications:

- Tsevere forms of allergic reactions to aminoglycosides (gentamycin sulfate) and chicken eggs;

- primary immunodeficiency states, malignant blood diseases and neoplasms;

- a strong reaction (temperature rise above 40 ° C, edema, hyperemia> 8 cm in diameter at the site of vaccine administration) or complication of previous vaccine administration;

- pregnancy.

Note:

- HIV infection is not a contraindication to vaccination.

Dosing and Administration:

Immediately prior to use, the vaccine is diluted with diluent for live measles and mumps vaccine culture live live at a rate of 0.5 ml of solvent per vaccine dose of the vaccine.The vaccine should completely dissolve within 3 minutes. The dissolved vaccine has the form of a transparent pink or colorless liquid. Vaccine and solvent in ampoules (vials) with broken integrity, marking, and also when their physical properties (color, transparency, etc.), with expired shelf life, incorrectly stored, are not suitable for use.

Opening of ampoules (vials) and the vaccination procedure is carried out with strict adherence to aseptic and antiseptic rules. Ampoules in the place of incision are treated with 70% alcohol and break off, not allowing the alcohol to fall into the ampoule. When the vial is opened, only the central plate of the metal cap is removed and the open surface of the rubber plug is wiped with 70% alcohol. To dilute the vaccine, all the necessary volume of solvent is aspirated and transferred to an ampoule (vial) with a dry vaccine. After mixing, the vaccine is taken up by another needle in a sterile syringe and used for vaccination.

The vaccine is administered subcutaneously in a volume of 0.5 ml under the scapula or in the shoulder region (at the border between the lower and middle third of the shoulder from the outside), pretreating the skin at the injection site with 70% alcohol.

The dissolved vaccine is used immediately and is not subject to storage.

The vaccine is registered in the prescribed registration forms with the name of the preparation, the date of vaccination, the dose, the manufacturer, the serial number, the date of manufacture, the expiration date, the response to the vaccination.

Side effects:

In most children, the vaccinal process is asymptomatic.

Some children from 6 to 18 days may experience temperature reactions, mild hyperemia of the throat, rhinitis; less often - cough and conjunctivitis, lasting for 1-3 days. In isolated cases, slight malaise and a corneal rash are observed. In case of mass application of the vaccine, an increase in body temperature above 38.5 ° C should not be more than 2% of vaccinated.

Local reactions, as a rule, are absent. In rare cases, an insignificant hyperemia of the skin and mild edema, which go through 1-3 days without treatment.

Complications that develop very rarely include convulsive reactions that occur, most often, 6-10 days after vaccination, usually against a high temperature background, and allergic reactions that occur in the first 24-48 hours in children with allergic reactivity.

Note

- febrile convulsions in the anamnesis, as well as an increase in temperature above 38.5 ° C in the post-vaccination period is an indication for the appointment of antipyretics.

Interaction:

Vaccination against measles can be done simultaneously (on the same day) with other vaccinations of the National Calendar (against mumps, rubella, poliomyelitis, hepatitis B, pertussis, diphtheria, tetanus) or not earlier than 1 month after the previous vaccination.

After the administration of human immunoglobulin preparations, measles vaccines are given no earlier than 2 months. After the introduction of measles vaccine, immunoglobulin preparations can be administered no earlier than 2 weeks; If immunoglobulin is required before this time, measles vaccination should be repeated.

Special instructions:

Edit Warnings

Vaccinations are conducted:

- after acute infectious and non-infectious diseases, with exacerbation of chronic diseases - at the end of acute manifestations of the disease;

- with non-severe forms of acute respiratory viral infection, acute intestinal diseases, etc. - immediately after the normalization of temperature;

- after immunosuppressive therapy - 3-6 months after the end of treatment.

On the day of vaccination, the doctor (paramedic) conducts a survey and examines the vaccine with mandatory thermometry. These persons are responsible for the correctness of the vaccination.

Persons temporarily released from vaccinations should be monitored and vaccinated after withdrawal of contraindications.

Form release / dosage:

Lyophilizate for the preparation of a solution for subcutaneous administration.

Packaging:

The vaccine is produced at 1, 2 and 5 inoculation doses in an ampoule (vial).

In a pack of 10 ampoules or vials of vaccine, instructions for use, the knife is ampoule in case of using ampoules according to OST 42-485-85.

Storage conditions:

Storage and transportation in accordance with SP 3.3.2.1248-03 at temperatures from 0 to 8 ° C.

Keep out of the reach of children.

Shelf life:2 years.
The drug with expired shelf life is not subject to application.
Terms of leave from pharmacies:For hospitals
Registration number:P N001586 / 01
Date of registration:05.12.2007 / 11.08.2014
Expiration Date:Unlimited
The owner of the registration certificate:Vector WB SSC FGUNVector WB SSC FGUN Russia
Manufacturer: & nbsp
Information update date: & nbsp12.01.2017
Illustrated instructions
    Instructions
    Up